Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Rating of “Moderate Buy” from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $5.12.

A number of brokerages have commented on GUTS. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings upgraded Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Craig Hallum assumed coverage on Fractyl Health in a research report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research note on Thursday, June 4th.

Insiders Place Their Bets

In other Fractyl Health news, Director William Bradley acquired 68,493 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was bought at an average price of $0.73 per share, for a total transaction of $49,999.89. Following the purchase, the director owned 84,622 shares in the company, valued at $61,774.06. This represents a 424.66% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ian Sheffield acquired 35,000 shares of Fractyl Health stock in a transaction dated Wednesday, June 10th. The shares were acquired at an average cost of $0.73 per share, with a total value of $25,550.00. Following the completion of the acquisition, the director directly owned 35,000 shares in the company, valued at $25,550. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 171,493 shares of company stock valued at $127,150. Corporate insiders own 8.52% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC acquired a new stake in Fractyl Health during the third quarter valued at approximately $19,298,000. 683 Capital Management LLC raised its holdings in shares of Fractyl Health by 30.1% in the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock worth $13,305,000 after buying an additional 1,397,620 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Fractyl Health by 234.9% during the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock worth $13,039,000 after buying an additional 4,156,969 shares during the period. Pale Fire Capital SE lifted its position in shares of Fractyl Health by 84.5% during the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after buying an additional 2,711,103 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new stake in Fractyl Health in the 3rd quarter valued at $8,981,000.

Fractyl Health Stock Down 4.5%

Shares of GUTS opened at $0.69 on Thursday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The company has a 50-day simple moving average of $0.80 and a 200-day simple moving average of $0.77. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $2.44. The firm has a market capitalization of $109.47 million, a P/E ratio of -0.53 and a beta of 2.29.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. On average, equities research analysts expect that Fractyl Health will post -0.6 earnings per share for the current year.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.